Mahamaya Lifesciences IPO Details
SME
Mahamaya Lifesciences IPO opens for subscription on 11 Nov 2025 and closes on 13 Nov 2025. The IPO will be listed on BSE with the tentative listing date set for 18 Nov 2025.
Mahamaya Lifesciences IPO price band has been fixed at ₹108 – ₹114 per share.The face value is ₹10 per share with a lot size of 1200.
Mahamaya Lifesciences IPO total issue size comprises 61,78,800 shares (aggregating up to ₹70.44 Cr.). This includes a fresh issue of 56,38,800 shares (aggregating up to ₹64.28 Cr.). Offer for Sale consists of 5,40,000 shares (aggregating up to ₹6.16 Cr.). Pre-issue shareholding stands at 1,77,66,200, which will increase to 2,34,05,000 post-issue.
Mahamaya Lifesciences IPO Lot Size : Individual Minimum is 2 lots (2,400 shares) amounting to ₹273,600. Individual Maximum is 2 lots (2,400 shares) amounting to ₹273,600. SHNI Minimum is 3 lots (3,600 shares) amounting to ₹410,400. SHNI Maximum is 7 lots (8,400 shares) amounting to ₹957,600. BHNI Minimum is 8 lots (9,600 shares) amounting to ₹1,094,400.
The Lead Managers for Mahamaya Lifesciences IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Oneview Corporate Advisors Pvt. Ltd.. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Mansi Share & Stock Broking Private Limited. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Mahamaya Lifesciences Limited RHP.
Mahamaya Lifesciences IPO Details
Mahamaya Lifesciences IPO Subscription
Mahamaya Lifesciences IPO Application Wise Breakup
Mahamaya Lifesciences IPO Dates
- 11 Nov 2025Opening dateOPD
- 13 Nov 2025Closing dateCOD
- 14 Nov 2025Allotment Date BOA
- 17 Nov 2025Initiation of RefundsIOR
- 17 Nov 2025Credit of SharesCOS
- 18 Nov 2025Listing dateLID
Mahamaya Lifesciences IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 2400 | ₹273,600 |
| Individual Maximum | 2 | 2400 | ₹273,600 |
| SHNI Minimum | 3 | 3600 | ₹410,400 |
| SHNI Maximum | 7 | 8400 | ₹957,600 |
| BHNI Minimum | 8 | 9600 | ₹1,094,400 |
Mahamaya Lifesciences IPO Reservation
Promoter Holding
Mahamaya Lifesciences IPO Valuations
Mahamaya Lifesciences Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 218.87 | 188.35 | 112.07 | 77.88 |
| Total Income | 84.04 | 267.17 | 162.83 | 137.40 |
| Profit After Tax | 4.10 | 12.94 | 5.22 | 3.75 |
| EBITDA | 8.04 | 24.64 | 13.36 | 8.91 |
| NET Worth | 53.50 | 49.42 | 24.66 | 19.44 |
| Reserves and Surplus | 35.73 | 31.66 | 23.41 | 18.19 |
| Total Borrowing | 57.72 | 58.11 | 54.63 | 24.37 |
| Amount in ₹ Crore | ||||
About Mahamaya Lifesciences IPO
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management and to help the farming community for more productivity.
The company specializes in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs).
The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).
The company has invested in global product registrations, with active markets in countries like the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations.
Product Portfolio:
- Bulk Formulations Sales: Acetamiprid, SP Buprofezin, SC Emamectin benzoate, SG Imidacloprid, SC Paraquat Dichloride.
- Technical Sales: Acetamiprid Technical 99% Min, Atrazine Technical 95% Min, Imidacloprid Technical 95% Min, Emamectin Benzoate Technical 95% Min.
- Branded Sales (Major own branded products): MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, UCHIT EW 370
- Export Sales- Formulations: Wiper (Sulphur 80% WDG), Lancha (Pendimethalin 50% EC), Tolfen (Tolfenpyrad 15% EC), Typic (80% Sulphur WG).
Strength Of Mahamaya Lifesciences IPO
- Experienced management team consisting of experts.
- Capability to introduce vital products for Indian Agriculture.
- Development of export opportunities of products.
- Ability to develop brands.
- Cordial relationships with suppliers of raw materials.
- Core values focused on achieving sustainability through innovative approaches.
- Established distribution network across various geographies through many dealers.
Risk Of Mahamaya Lifesciences IPO
- Our top ten customers constituted 71.35%, 76.26%, 83.14% and 71.12% of our sales for the period ended June 30, 2025 and for the financial year ended March 31, 2025, March 31, 2024, March 31, 2023 respectively. Absence of large number of customers, dependence on few customers and creating a customer concentration risk which may have an adverse impact on our business operations and financial performance.
- The Company has not entered into long-term agreements with its customers for purchasing the company products nor for the supply of raw materials with its suppliers. The company is subject to uncertainties in demand/supply and there is no assurance that these customers and suppliers will continue to purchase its products or sell raw materials to it or that they will not scale down their orders. This could impact the business and financial performance of the Company.
- Raw materials constitute a significant percentage of the Company's total expenses. Any increase in prices and any decrease in the supply would materially adversely affect the Company's business.
- The company is required to obtain and/or renew certain registrations from the CIB&RC for its products manufactured in India. The company also register its products in overseas jurisdictions through the company International Distribution Partners to enable exports to such countries. Any failure to successfully register its products in India or in the international markets may affect its results of operations and financial condition.
- The company has complied with the timely filing requirement for statutory dues but have faced delays in payment due to technical issue.
- The company is party to certain litigation and claims. These legal proceedings are pending at different levels of adjudication before various forums and regulatory authorities. Any adverse decision may make us liable to liabilities /penalties and may adversely affect its reputation, business, and financial status.
- Perception of non-compliance due to non-reflection of TDS payment on the TRACES Portal.
- Its may not be able to avail funding from banks or financial institution for the company future working capital requirements. The failures to obtain such financing may adversely affect its ability to grow and the company future profitability.
- The Objects of the Offer for which funds are being raised have not been appraised by any bank or financial institution. The deployment of funds is entirely at the discretion of its management and as per the details mentioned in the section titled "Objects of the Offer". Any revision in the estimates may require it to reschedule the company expenditure and may have a bearing on its expected revenues and earnings.
- The Company had negative cash flows, details of which are given below. Sustained negative cash flow could adversely impact its business, financial condition and results of operations.
Objectives Mahamaya Lifesciences IPO
- Purchase of Equipment for existing Formulation plant.
- Funding capital expenditure towards setting up of a new Technical manufacturing plant.
- Construction of Warehouse Building and Purchase of Machinery.
- Funding working capital requirement of the Company.
- General Corporate purposes.
Company Contact Details
Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Market Maker
Market Maker Reports
Read more about Mahamaya Lifesciences Limited IPO
- Mahamaya Lifesciences Limited IPO Detail
- Mahamaya Lifesciences Limited IPO Subscription Detail
- Mahamaya Lifesciences Limited IPO GMP Detail
- Checked Live Mahamaya Lifesciences Limited IPO Allotment Status
- Mahamaya Lifesciences Limited IPO Basis Of Allotment
- Mahamaya Lifesciences Limited IPO Price Calculator
- Mahamaya Lifesciences Limited IPO Stock Price